Astria Therapeutics, Inc.
US ˙ NasdaqGM ˙ US04635X1028

Introduction

This page provides a comprehensive analysis of the known insider trading history of Svlsf V, Llc. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Svlsf V, Llc has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:BCYC / Bicycle Therapeutics plc - Depositary Receipt (Common Stock) 10% Owner 0
US:STRO / Sutro Biopharma, Inc. 10% Owner 0
US:ASNS / Actelis Networks, Inc. 10% Owner 0
US:CATB / Astria Therapeutics Inc 10% Owner 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Svlsf V, Llc. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases ATXS / Astria Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ATXS / Astria Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2015-06-30 CATB SVLSF V, LLC 382,996 12.0000 38,300 120.0000 4,595,952 23 870 28,724,178 624.99
2015-06-30 CATB SVLSF V, LLC 8,094 12.0000 809 120.0000 97,128

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ATXS / Astria Therapeutics, Inc. Insider Trades
Insider Sales ATXS / Astria Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ATXS / Astria Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ATXS / Astria Therapeutics, Inc. Insider Trades
Insider Purchases BCYC / Bicycle Therapeutics plc - Depositary Receipt (Common Stock) - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ATXS / Astria Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2019-05-28 BCYC SVLSF V, LLC 377,732 14.0000 377,732 14.0000 5,288,248 366 18.15 1,567,588 29.64
2019-05-28 BCYC SVLSF V, LLC 7,983 14.0000 7,983 14.0000 111,762

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

BCYC / Bicycle Therapeutics plc - Depositary Receipt (Common Stock) Insider Trades
Insider Sales BCYC / Bicycle Therapeutics plc - Depositary Receipt (Common Stock) - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ATXS / Astria Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

BCYC / Bicycle Therapeutics plc - Depositary Receipt (Common Stock) Insider Trades
Insider Purchases STRO / Sutro Biopharma, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ATXS / Astria Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

STRO / Sutro Biopharma, Inc. Insider Trades
Insider Sales STRO / Sutro Biopharma, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ATXS / Astria Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

STRO / Sutro Biopharma, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Svlsf V, Llc as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2019-05-30 2019-05-28 4 BCYC BICYCLE THERAPEUTICS plc
Series B1 Preferred Shares
C - Conversion -13,169 0 -100.00
2019-05-30 2019-05-28 4 BCYC BICYCLE THERAPEUTICS plc
Series A Preferred Shares
C - Conversion -18,485 0 -100.00
2019-05-30 2019-05-28 4 BCYC BICYCLE THERAPEUTICS plc
Series B1 Preferred Shares
C - Conversion -623,196 0 -100.00
2019-05-30 2019-05-28 4 BCYC BICYCLE THERAPEUTICS plc
Series A Preferred Shares
C - Conversion -874,709 0 -100.00
2019-05-30 2019-05-28 4 BCYC BICYCLE THERAPEUTICS plc
Ordinary Shares
P - Purchase 7,983 39,637 25.22 14.00 111,762 554,918
2019-05-30 2019-05-28 4 BCYC BICYCLE THERAPEUTICS plc
Ordinary Shares
P - Purchase 377,732 1,875,637 25.22 14.00 5,288,248 26,258,918
2019-05-30 2019-05-28 4 BCYC BICYCLE THERAPEUTICS plc
Ordinary Shares
C - Conversion 13,169 31,654 71.24
2019-05-30 2019-05-28 4 BCYC BICYCLE THERAPEUTICS plc
Ordinary Shares
C - Conversion 18,485 18,485
2019-05-30 2019-05-28 4 BCYC BICYCLE THERAPEUTICS plc
Ordinary Shares
C - Conversion 623,196 1,497,905 71.25
2019-05-30 2019-05-28 4 BCYC BICYCLE THERAPEUTICS plc
Ordinary Shares
C - Conversion 874,709 874,709
2018-10-01 2018-10-01 4 STRO SUTRO BIOPHARMA INC
Series E Preferred Stock
C - Conversion -193,492 0 -100.00
2018-10-01 2018-10-01 4 STRO SUTRO BIOPHARMA INC
Series D Preferred Stock
C - Conversion -141,249 0 -100.00
2018-10-01 2018-10-01 4 STRO SUTRO BIOPHARMA INC
Series C Preferred Stock
C - Conversion -194,786 0 -100.00
2018-10-01 2018-10-01 4 STRO SUTRO BIOPHARMA INC
Series E Preferred Stock
C - Conversion -9,155,794 0 -100.00
2018-10-01 2018-10-01 4 STRO SUTRO BIOPHARMA INC
Series D Preferred Stock
C - Conversion -6,683,697 0 -100.00
2018-10-01 2018-10-01 4 STRO SUTRO BIOPHARMA INC
Series C Preferred Stock
C - Conversion -9,217,015 0 -100.00
2018-10-01 2018-10-01 4 STRO SUTRO BIOPHARMA INC
Series C Preferred Stock
C - Conversion -52,183 0 -100.00
2018-10-01 2018-10-01 4 STRO SUTRO BIOPHARMA INC
Series B Preferred Stock
C - Conversion -106,019 0 -100.00
2018-10-01 2018-10-01 4 STRO SUTRO BIOPHARMA INC
Series A Preferred Stock
C - Conversion -17,533 0 -100.00
2018-10-01 2018-10-01 4 STRO SUTRO BIOPHARMA INC
Series C Preferred Stock
C - Conversion -5,462,550 0 -100.00
2018-10-01 2018-10-01 4 STRO SUTRO BIOPHARMA INC
Series B Preferred Stock
C - Conversion -11,097,596 0 -100.00
2018-10-01 2018-10-01 4 STRO SUTRO BIOPHARMA INC
Series A Preferred Stock
C - Conversion -1,835,270 0 -100.00
2018-10-01 2018-10-01 4 STRO SUTRO BIOPHARMA INC
Series C Preferred Stock
C - Conversion -64,815 0 -100.00
2018-10-01 2018-10-01 4 STRO SUTRO BIOPHARMA INC
Series B Preferred Stock
C - Conversion -131,683 0 -100.00
2018-10-01 2018-10-01 4 STRO SUTRO BIOPHARMA INC
Series A Preferred Stock
C - Conversion -21,776 0 -100.00
2018-10-01 2018-10-01 4 STRO SUTRO BIOPHARMA INC
Common Stock
C - Conversion 5,320 18,248 41.15
2018-10-01 2018-10-01 4 STRO SUTRO BIOPHARMA INC
Common Stock
C - Conversion 5,721 12,928 79.38
2018-10-01 2018-10-01 4 STRO SUTRO BIOPHARMA INC
Common Stock
C - Conversion 7,207 7,207
2018-10-01 2018-10-01 4 STRO SUTRO BIOPHARMA INC
Common Stock
C - Conversion 251,783 863,503 41.16
2018-10-01 2018-10-01 4 STRO SUTRO BIOPHARMA INC
Common Stock
C - Conversion 270,690 611,720 79.37
2018-10-01 2018-10-01 4 STRO SUTRO BIOPHARMA INC
Common Stock
C - Conversion 341,030 341,030
2018-10-01 2018-10-01 4 STRO SUTRO BIOPHARMA INC
Common Stock
C - Conversion 1,931 8,817 28.04
2018-10-01 2018-10-01 4 STRO SUTRO BIOPHARMA INC
Common Stock
C - Conversion 6,128 6,886 808.44
2018-10-01 2018-10-01 4 STRO SUTRO BIOPHARMA INC
Common Stock
C - Conversion 758 758
2018-10-01 2018-10-01 4 STRO SUTRO BIOPHARMA INC
Common Stock
C - Conversion 202,115 923,022 28.04
2018-10-01 2018-10-01 4 STRO SUTRO BIOPHARMA INC
Common Stock
C - Conversion 641,440 720,907 807.18
2018-10-01 2018-10-01 4 STRO SUTRO BIOPHARMA INC
Common Stock
C - Conversion 79,467 79,467
2018-10-01 2018-10-01 4 STRO SUTRO BIOPHARMA INC
Common Stock
C - Conversion 2,399 10,952 28.05
2018-10-01 2018-10-01 4 STRO SUTRO BIOPHARMA INC
Common Stock
C - Conversion 7,610 8,553 807.00
2018-10-01 2018-10-01 4 STRO SUTRO BIOPHARMA INC
Common Stock
C - Conversion 943 943
2018-10-01 2018-09-27 4 STRO SUTRO BIOPHARMA INC
Series C Preferred Stock
M - Exercise 4,978 52,183 10.55
2018-10-01 2018-09-27 4 STRO SUTRO BIOPHARMA INC
Series C Preferred Stock Warrant (right to buy)
M - Exercise -4,978 4,315 -53.57
2018-10-01 2018-09-27 4 STRO SUTRO BIOPHARMA INC
Series C Preferred Stock
M - Exercise 521,159 5,462,550 10.55
2018-10-01 2018-09-27 4 STRO SUTRO BIOPHARMA INC
Series C Preferred Stock Warrant (right to buy)
M - Exercise -521,159 451,869 -53.56
2018-10-01 2018-09-27 4 STRO SUTRO BIOPHARMA INC
Series C Preferred Stock
M - Exercise 6,183 64,815 10.55
2018-10-01 2018-09-27 4 STRO SUTRO BIOPHARMA INC
Series C Preferred Stock Warrant (right to buy)
M - Exercise -6,183 5,361 -53.56
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series D Convertible Preferred Stock
C - Conversion -50,477 0 -100.00
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series D Convertible Preferred Stock
C - Conversion -1,474,348 0 -100.00
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series D Convertible Preferred Stock
C - Conversion -14,635 0 -100.00
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series D Convertible Preferred Stock
C - Conversion -692,552 0 -100.00
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series C Convertible Preferred Stock
C - Conversion -4,747 0 -100.00
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series C Convertible Preferred Stock
C - Conversion -224,665 0 -100.00
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series B Convertible Preferred Stock
C - Conversion -15,246 0 -100.00
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series B Convertible Preferred Stock
C - Conversion -721,402 0 -100.00
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series A-2 Convertible Preferred Stock
C - Conversion -14,587 0 -100.00
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series A-2 Convertible Preferred Stock
C - Conversion -690,259 0 -100.00
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series A-1 Convertible Preferred Stock
C - Conversion -1,380 0 -100.00
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series A-1 Convertible Preferred Stock
C - Conversion -65,287 0 -100.00
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock
P - Purchase 16,552 1,868,961 0.89 10.00 165,520 18,689,610
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock
P - Purchase 483,448 1,852,409 35.31 10.00 4,834,480 18,524,090
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock
C - Conversion 14,789 1,368,961 1.09
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock
C - Conversion 431,980 1,354,172 46.84
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock
C - Conversion 4,288 922,192 0.47
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock
C - Conversion 202,915 917,904 28.38
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock
C - Conversion 2,365 714,989 0.33
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock
C - Conversion 111,955 712,624 18.64
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock
C - Conversion 6,806 600,669 1.15
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock
C - Conversion 322,102 593,863 118.52
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock
C - Conversion 5,219 271,761 1.96
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock
C - Conversion 247,010 266,542 1,264.64
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock
C - Conversion 404 19,532 2.11
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock
C - Conversion 19,128 19,128
2015-06-30 2015-06-30 4 CATB CATABASIS PHARMACEUTICALS INC
Series B Preferred Stock
C - Conversion -207,558 0 -100.00
2015-06-30 2015-06-30 4 CATB CATABASIS PHARMACEUTICALS INC
Series B Preferred Stock
C - Conversion -9,821,385 0 -100.00
2015-06-30 2015-06-30 4 CATB CATABASIS PHARMACEUTICALS INC
Series A Preferred Stock
C - Conversion -448,414 0 -100.00
2015-06-30 2015-06-30 4 CATB CATABASIS PHARMACEUTICALS INC
Series A Preferred Stock
C - Conversion -21,218,253 0 -100.00
2015-06-30 2015-06-30 4 CATB CATABASIS PHARMACEUTICALS INC
Common Stock
P - Purchase 8,094 59,139 15.86 12.00 97,128 709,668
2015-06-30 2015-06-30 4 CATB CATABASIS PHARMACEUTICALS INC
Common Stock
P - Purchase 382,996 2,798,528 15.86 12.00 4,595,952 33,582,336
2015-06-30 2015-06-30 4 CATB CATABASIS PHARMACEUTICALS INC
Common Stock
C - Conversion 16,152 51,045 46.29
2015-06-30 2015-06-30 4 CATB CATABASIS PHARMACEUTICALS INC
Common Stock
C - Conversion 764,309 2,415,532 46.29
2015-06-30 2015-06-30 4 CATB CATABASIS PHARMACEUTICALS INC
Common Stock
C - Conversion 34,893 34,893
2015-06-30 2015-06-30 4 CATB CATABASIS PHARMACEUTICALS INC
Common Stock
C - Conversion 1,651,223 1,651,223
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)